Kura Oncology Valuation
| KURA Stock | USD 10.06 5.85 36.77% |
At this time, the firm appears to be undervalued. Kura Oncology secures a last-minute Real Value of $14.39 per share. The latest price of the firm is $10.06. Our model forecasts the value of Kura Oncology from analyzing the firm fundamentals such as Shares Owned By Insiders of 1.05 %, current valuation of 798.55 M, and Return On Equity of -0.46 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Kura Oncology's valuation include:
Price Book 2.9196 | Enterprise Value 798.6 M | Enterprise Value Ebitda (2.48) |
Undervalued
Today
Please note that Kura Oncology's price fluctuation is somewhat reliable at this time. Calculation of the real value of Kura Oncology is based on 3 months time horizon. Increasing Kura Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kura Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kura Stock. However, Kura Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.06 | Real 14.39 | Target 29.88 | Hype 10.2 | Naive 11.09 |
The real value of Kura Stock, also known as its intrinsic value, is the underlying worth of Kura Oncology Company, which is reflected in its stock price. It is based on Kura Oncology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kura Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kura Oncology helps investors to forecast how Kura stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kura Oncology more accurately as focusing exclusively on Kura Oncology's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Kura Oncology's intrinsic value based on its ongoing forecasts of Kura Oncology's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Kura Oncology's closest peers. If more than one evaluation category is relevant for Kura Oncology we suggest using both methods to arrive at a better estimate.
Kura Oncology Cash |
|
Kura Valuation Trend
Comparing Kura Oncology's enterprise value against its market capitalization is a good way to estimate the value of Kura Oncology uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Kura Oncology Total Value Analysis
Kura Oncology is now projected to have valuation of 798.55 M with market capitalization of 1.24 B, debt of 17.2 M, and cash on hands of 450.26 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Kura Oncology fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
798.55 M | 1.24 B | 17.2 M | 450.26 M |
Kura Oncology Asset Utilization
One of the ways to look at asset utilization of Kura is to check how much profit was generated for every dollar of assets it reports. Kura Oncology secures a negative usage of assets of -0.29 %, losing $0.002854 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Kura Oncology shows how discouraging it operates for each dollar spent on its assets.Kura Oncology Ownership Allocation
The majority of Kura Oncology outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kura Oncology to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kura Oncology. Please pay attention to any change in the institutional holdings of Kura Oncology as this could imply that something significant has changed or is about to change at the company.Kura Oncology Profitability Analysis
Net Loss for the year was (152.63 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kura Oncology's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kura Oncology and how it compares across the competition.
About Kura Oncology Valuation
The stock valuation mechanism determines Kura Oncology's current worth on a weekly basis. Our valuation model uses a comparative analysis of Kura Oncology. We calculate exposure to Kura Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kura Oncology's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -849 K | -806.5 K |
Kura Oncology Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 73.2 M |
Kura Oncology Current Valuation Indicators
Valuation refers to the process of determining the present value of Kura Oncology and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Kura we look at many different elements of the entity such as Kura's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Kura Oncology, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Kura Oncology's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Kura Oncology's worth.Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |